1[1]Josse R, Thomas. A review of 10 years of experience with indapamide as an antihypertensive agent[J].Hypertension, 1985,7:SupplⅡ152-1155.
2[2]Morledge JH. Clinical efficacy and safety of indapamide in essentialhypertension[J].Am Heart J,1983,106:229-232.
3[3]Wheeley MSTG, Bolton JC, Campbekk DB. Indapamide in hypertension: a study in general practice of new or previously poorly controlled patients[J].Pharmocotherap-eutica,1982,3:143-152.
4[4]Andries EW, Brems HM, Clement DL. Long-term effects of indapamide in patients with essential hypertension[J].Excerpta Medica, 1980:182-190.
5[5]Belings, Vukovich RA, Neiss ES, Zisblatt M. Long-term experience with indapamide[J].Am Heart J,1983,106:258-262.
6[6]Anavekar SN, Ludbrook A, louis WJ. Evalution of indapamide in the treatment of hypertension[J].J Cardiovasc Pharmocol,1979,1:389-394.
7[7]Rowlands DB, Glover DR, Young MA. Once-daily indapamide in the treatment of the elderly and young hypertensive[J].Eur J Clin Pharmocal,1984,27:397-405.
8[8]Donald Weidler MD, Nadeer S, Jallad phD, et al. Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension[J].J Clin pharmacol,1995,35:45-51.
9[9]Asmar R, Guez D, Malbezin M, et al. Therapeutic benefit of a low dose of indapamide:results of a double-blind against placebo European controlled study [in French][J].Arch Mal Coeur vaiss,1995,88:1083-7.
10[10]Anbrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomized double-blind controlled studies[J].J Hypertens, 1998,16:1677-84.
